跳转至内容
Merck
CN

762881

Sigma-Aldrich

Poly(N-isopropylacrylamide-co-butylacrylate)

butylacrylate 12 mol %, average Mn 30,000

别名:

NIPAM, 聚(N-异丙基丙烯酰胺)

登录查看公司和协议定价


About This Item

线性分子式:
(C6H11NO)m(C7H12O2)n
UNSPSC代码:
12162002
NACRES:
NA.23

形式

solid

质量水平

投料比

NIPAM:BA 8:1

分子量

average Mn 30,000

组成

butylacrylate, 12 mol %

转变温度

LCST 14-16 °C

PDI

1.51

正在寻找类似产品? 访问 产品对比指南

相关类别

一般描述

Random copolymer of N-isopropylacrylamide with 12 mole % butylacrylate. This copolymer shows LCST at 15 C (lower temperature than PolyNIPAM).

应用

Thermosensitive polymer; can be used to form a hydrogel. Aqueous polymer solution undergoes a phase transition from a soluble to an insoluble state when the temperature is raised to ca. 15 °C.

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

G Chen et al.
Nature, 373(6509), 49-52 (1995-01-05)
There are many potential applications of 'intelligent' aqueous polymer systems in medicine, biotechnology, industry and in environmental problems. Many of these polymer systems undergo reversible phase transitions--for example, abrupt changes in volume--in response to external stimuli such as temperature, pH
A Gutowska et al.
Journal of biomedical materials research, 29(7), 811-821 (1995-07-01)
Biomer/poly(N-isopropylacrylamide)/[poly(NiPAAm)] thermosensitive polymer blends were prepared and their application as heparin-releasing polymer coatings for the prevention of surface-induced thrombosis was examined. The advantage of using poly (NiPAAm)-based coatings as heparin-releasing polymers is based on the unique temperature-dependent swelling of these

商品

By altering the physicochemical properties, smart or intelligent drug delivery systems can be designed to deliver therapeutic molecules on-demand. Learn more about the application of stimuli-responsive materials in drug delivery.

通过调整的理化特性,药物递送系统可根据需要设计为可递送治疗分子的智能系统。了解有关刺激响应材料药物递送应用的更多信息。

Immunosuppressive tumor-associated myeloid cells (TAMC) are responsible for glioblastoma (GBM) resistance to immunotherapies and existing standard of care treatments. This mini-review highlights recent progress in implementing nanotechnology in advancing TAMC-targeted therapies for GBM.

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门